Burcon Nutrascience Corporation (TSX: BU) is moving into a new phase of operations, having completed commissioning and launched commercial production across its Peazazz pea protein, Puratein C canola protein, and FavaPro fava protein lines in fiscal year 2026, according to an update from Stonegate Capital Partners. The company reported revenue of $0.83 million in the fourth quarter of fiscal 2026, up from $0.74 million in the third quarter, with management indicating that sales in the current quarter are tracking toward approximately 50% sequential growth based on April and May activity.
The milestone marks a shift from commissioning to early utilization at its Galesburg facility, with growing customer volumes setting up improved fixed-cost absorption. Burcon also set a new production record, with daily output roughly 60% above January-March levels. As volume builds, the margin opportunity is expected to come from better utilization, a steadier production cadence, and the removal of start-up costs from the run-rate cost structure, rather than from pricing alone.
Customer traction is broadening, with more than 30 purchasing customers and over 200 active projects spanning pea, canola, and fava applications. The company has secured funding to support the Galesburg scale-up, with $6.9 million completed, $3.0 million undrawn, and management targeting $10 million in calendar year 2026 sales. For leaders in the business and technology sectors, this development underscores the growing commercial viability of plant-based proteins and the potential for specialized ingredient manufacturers to capture value as production scales. The ramp in utilization and customer adoption could signal a turning point for Burcon as it moves toward profitability, with implications for the broader alternative protein industry that has faced production and cost challenges.
Stonegate Capital Partners, a capital markets advisory firm, provided the update. More details can be found in the full announcement.
